Tag: Enfuvirtide

Approved by the FDA in 2003, enfuvirtide was the first HIV fusion inhibitor, representing a new class of antiretroviral drugs. This innovative medication provides a crucial treatment option for individuals whose virus has developed resistance to other HIV therapies by targeting the viral entry process.

As the first approved HIV fusion inhibitor, Fuzeon (enfuvirtide) marked a major step forward in addressing the unmet needs of patients with limited treatment options. **What does Fuzeon treat?** It is a critical medication for treating multidrug-resistant human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients who have experienced treatment failure with other antiretroviral therapies.

First approved in 2003, enfuvirtide was a significant breakthrough as the first HIV fusion inhibitor, but it was primarily reserved for treatment-experienced patients with multi-drug resistant HIV-1. The drug, marketed under the brand name Fuzeon, addresses the critical need for a treatment option when standard regimens fail.

Approved by the FDA in 2003, Fuzeon was the first medication of its kind to target the fusion step of the HIV lifecycle. This powerful antiretroviral helps answer the question, **what does Fuzeon do?**, by explaining its unique action against the virus in treatment-experienced patients.